


## T-2513 hydrochloride

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-125930A  |
| <b>CAS No.:</b>           | 187793-52-8   |
| <b>Molecular Formula:</b> | C <sub>25</sub> H <sub>28</sub> ClN <sub>3</sub> O <sub>5</sub>                           |
| <b>Molecular Weight:</b>  | 485.96  |
| <b>Target:</b>            | Topoisomerase; DNA/RNA Synthesis  |
| <b>Pathway:</b>           | Cell Cycle/DNA Damage   |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |  |               |  |                |                      |                  |          |         |   |
|-------------------------------------|--|---------------|--|----------------|----------------------|------------------|----------|---------|---|
| <b>Description</b>                  | T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death <sup>[1]</sup> .   |               |  |                |                      |                  |          |         |   |
| <b>IC<sub>50</sub> &amp; Target</b> | Topoisomerase I  |               |  |                |                      |                  |          |         |   |
| <b>In Vitro</b>                     | <p>SN-38 is the metabolite of T-2513 hydrochloride<sup>[1]</sup>.</p> <p>T-2513 hydrochloride has a broad cytotoxicity against a range of human tumor cell lines<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells</td> </tr> <tr> <td>Concentration:</td> <td>15.1-111.5 ng/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Exhibited cytotoxicity against a panel of human tumor cell lines with GI<sub>50</sub>s of 32.1, 97.6, 38.6, 15.6, 111.5, 15.1, 34.0, and 50.9 ng/mL for WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells, respectively.</td> </tr> </table> | Cell Line:    | WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells | Concentration: | 15.1-111.5 ng/mL     | Incubation Time: | 24 hours | Result: | Exhibited cytotoxicity against a panel of human tumor cell lines with GI <sub>50</sub> s of 32.1, 97.6, 38.6, 15.6, 111.5, 15.1, 34.0, and 50.9 ng/mL for WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells, respectively. |
| Cell Line:                          | WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells   |               |  |                |                      |                  |          |         |   |
| Concentration:                      | 15.1-111.5 ng/mL   |               |  |                |                      |                  |          |         |   |
| Incubation Time:                    | 24 hours   |               |  |                |                      |                  |          |         |   |
| Result:                             | Exhibited cytotoxicity against a panel of human tumor cell lines with GI <sub>50</sub> s of 32.1, 97.6, 38.6, 15.6, 111.5, 15.1, 34.0, and 50.9 ng/mL for WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells, respectively.  |               |  |                |                      |                  |          |         |   |
| <b>In Vivo</b>                      | <p>T-2513 hydrochloride (1-100 mg/kg) shows Antitumor Activity against Walker-256 carcinoma<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rats bearing Walker-256 carcinoma<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 10, and 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td></td> </tr> <tr> <td>Result:</td> <td>The ED<sub>50</sub> was 23 mg/kg.</td> </tr> </table>  | Animal Model: | Rats bearing Walker-256 carcinoma <sup>[2]</sup>                 | Dosage:        | 1, 10, and 100 mg/kg | Administration:  |          | Result: | The ED <sub>50</sub> was 23 mg/kg.  |
| Animal Model:                       | Rats bearing Walker-256 carcinoma <sup>[2]</sup>   |               |  |                |                      |                  |          |         |   |
| Dosage:                             | 1, 10, and 100 mg/kg   |               |  |                |                      |                  |          |         |   |
| Administration:                     |  |               |  |                |                      |                  |          |         |   |
| Result:                             | The ED <sub>50</sub> was 23 mg/kg.   |               |  |                |                      |                  |          |         |   |

### REFERENCES

---

[1]. Stephan A Veltkamp, et al. Clinical and pharmacologic study of the novel prodrug delimitotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res. 2008 Nov 15;14(22):7535-44.

[2]. S Okuno, et al. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA